You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CAR T cell, CD19, pediatric, young adults

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma Trial in Minsk (CD19 CAR-T-cells, Tocilizumab)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Lymphoblastic B-Cell Lymphoma
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Apr 12, 2022

Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma Trial in Seattle (second generation 4-1BB? EGFR806-EGFRt, second

Recruiting
  • Pediatric Solid Tumor
  • +15 more
  • second generation 4-1BBζ EGFR806-EGFRt
  • second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
  • Seattle, Washington
    Seattle Children's Hospital
May 2, 2022

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric Trial in Moscow (Chimeric Antigen Receptor T-Cell

Unknown status
  • B-cell Acute Lymphoblastic Leukemia
  • Acute Lymphocytic Leukemia, Pediatric
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Moscow, Russian Federation
    Dmitry Rogachev National Research Center of Pediatric Hematology
Apr 7, 2021

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

Suspended
  • B Cell Lymphoma
  • +2 more
  • Stanford, California
    Stanford Medical Center
Sep 8, 2022

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 3, 2023

Acute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell Trial in Ramat Gan (CD19 CAR T cells)

Unknown status
  • Acute Lymphoblastic Leukemia, B-precursor
  • Non-Hodgkin Lymphoma, B-cell
  • CD19 CAR T cells
  • Ramat Gan, Israel
    Chaim Sheba Medical Center
Nov 1, 2020

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

B Acute Lymphoblastic Leukemia Trial in Duarte (drug, procedure, other)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Autologous Anti-CD19 CAR-expressing T Lymphocytes
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

Withdrawn
  • T-cell Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma
  • Target CD7 CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022

Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 CAR-T cell infusion
  • (no location specified)
Oct 24, 2023

B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

Recruiting
  • B-Cell Leukemia
  • +2 more
  • Anti-CD19 Autologous CAR-T Cell Infusion
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

CD 19+ Acute Leukemia Trial in Seattle (T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC))

Active, not recruiting
  • CD 19+ Acute Leukemia
  • T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
  • Seattle, Washington
    Seattle Children's Hospital
Mar 22, 2022